Mid-Term Outcomes of ‘Covered Endovascular Reconstruction of Iliac Bifurcation: The ‘CERIB’ Technique
Annals of Vascular Surgery · 2026-12 · 133 · 836-846
DOI: 10.1016/j.avsg.2026.08.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Vascular Surgery, 2026-12. Verfasst von Miltiadis Matsagkas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Surgery Department, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Endovascular Aneurysm Repair, Blood Vessel Prosthesis, Iliac Aneurysm, Blood Vessel Prosthesis Implantation. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The aim of this study is to present the 30-day and mid-term outcomes of the off-the-shelf covered endovascular reconstruction of iliac bifurcation (CERIB) technique in patients managed with endovascular repair for aortoiliac aneurysms. METHODS: A single-center retrospective analysis was conducted including patients with aorto-iliac aneurysms that received the CERIB technique from December 2022 to December 2025. Proximal repair of the aorta was performed either with standard endovascular aneurysm repair (EVAR) or complex EVAR. Mortality, patency, presence of endoleak (EL), and reinterventions were analyzed at 30 days and during mid-term period. RESULTS: Fifty-nine patients (mean age: 71.6 ± 6, 100% males) were included, receiving 78 CERIB procedures (19 bilaterally). Nineteen patients had previous endovascular aortic aneurysm repair and half of them (49%; 29/59) received primarily EVAR. The technical success was 100%. Two deaths (3,3%) were recorded in 2 fenestrated/branched endovascular aortic aneurysm repair (F/BEVAR) patients during 30-day postop period. The mean follow up was 12 ± 7 months, with one cancer-related death (1.7%; 1/57). Patency rate was estimated at 98% [standard error; (SE) 2%] at 12 months and remained the same with no further event during follow up. The freedom from gutter EL Ib rate was 96.8% (SE 2.2%) at 6 months and remained the same with no further event. The freedom from reintervention rate was 93.8% (SE 3%) at 6 months and remained the same with no further event. CONCLUSION: The CERIB technique represents an endovascular procedure for managing complex aorto-iliac pathology, with excellent technical success, favorable patency rates, low early complication and reintervention rates, and durable mid-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Vascular Surgery Department, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
- Anesthesiology Department, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
- Vascular Surgery Department, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. Electronic address: spanos.kon@gmail.com.
Zitieren
APA
Matsagkas, M., Nana, P., Chaidoulis, A., Kouvelos, G., Dakis, K., Batzalexis, K., Arnaoutoglou, E., & Spanos, K. (2026). Mid-Term Outcomes of ‘Covered Endovascular Reconstruction of Iliac Bifurcation: The ‘CERIB’ Technique. Annals of Vascular Surgery, 133, 836-846. https://doi.org/10.1016/j.avsg.2026.08.030
Vancouver
Matsagkas M, Nana P, Chaidoulis A, Kouvelos G, Dakis K, Batzalexis K, et al. Mid-Term Outcomes of ‘Covered Endovascular Reconstruction of Iliac Bifurcation: The ‘CERIB’ Technique. Annals of Vascular Surgery. 2026;133:836-846. doi:10.1016/j.avsg.2026.08.030
BibTeX
@article{Matsagkas2026,
author = {Matsagkas, Miltiadis and Nana, Petroula and Chaidoulis, Athanasios and Kouvelos, George and Dakis, Konstantinos and Batzalexis, Konstantinos and Arnaoutoglou, Eleni and Spanos, Konstantinos},
title = {Mid-Term Outcomes of ‘Covered Endovascular Reconstruction of Iliac Bifurcation: The ‘CERIB’ Technique},
journal = {Annals of Vascular Surgery},
year = {2026},
volume = {133},
pages = {836--846},
doi = {10.1016/j.avsg.2026.08.030}
}
EUVIMED